|1.||Segal, Corrinne V: 1 article (07/2015)|
|2.||Koufaris, Costas: 1 article (07/2015)|
|3.||Powell, Chris: 1 article (07/2015)|
|4.||Gooderham, Nigel J: 1 article (07/2015)|
|5.||Catalano, Stefania: 1 article (01/2014)|
|6.||Giordano, Francesca: 1 article (01/2014)|
|7.||Zito, Domenico: 1 article (01/2014)|
|8.||Mauro, Loredana: 1 article (01/2014)|
|9.||Sisci, Diego: 1 article (01/2014)|
|10.||De Amicis, Francesca: 1 article (01/2014)|
|1.||Prostatic Neoplasms (Prostate Cancer)
12/18/2005 - "Then human androgen-dependent prostate cancer cells LNCaP were used as a model to study the regulation of PTTG1 by Mibolerone. "
01/01/2002 - "In our study, LNCaP prostate cancer cells were treated with GA for 30 minutes or 24 hours, in the presence of mibolerone, a synthetic androgen. "
12/18/2005 - "The basic expression of PTTG1 in human androgen-independent prostate cancer cell lines PC3 or DU145 was even higher than that in the human androgen-dependent prostate cancer cells LNCaP treated with Mibolerone. "
05/01/1999 - "Prostate cancer cells were transiently transfected with each of the above-described expression vectors, incubated with or without androgen (mibolerone) for 48 h, and monitored for iodide uptake activity. "
01/01/2012 - "In follow-up studies, proliferation of WPE1-NA22 prostate cancer cells and parent line RWPE-1 prostate epithelial cells were unaltered by treatment with testosterone, dihydrotestosterone, or mibolerone, suggesting that these cell lines are not androgen-sensitive. "
|2.||Breast Neoplasms (Breast Cancer)
01/01/2014 - "Site-directed mutagenesis and deletion analysis reveal that an androgen response element (ARE), TGTTCT motif located at positions -383 and -377, is critical for mibolerone-induced ER-beta up-regulation in breast cancer cells. "
06/01/2008 - "Our results demonstrate that mibolerone can have both androgenic and progestagenic actions in breast cancer cells."
07/01/1993 - "T47D breast cancer cells showed a similar effect with mibolerone, while hAR expression in normal skin fibroblasts did not respond to androgen treatment. "
01/01/2014 - "In this study, we demonstrate that mibolerone, a synthetic androgen ligand, up-regulates ER-beta mRNA and protein levels in ER-positive breast cancer cells. "
06/01/2008 - "This study compared the effects of 5alpha-dihydrotestosterone (DHT) and a synthetic androgen, mibolerone, on estradiol (E(2))-induced proliferation of breast cancer cells. "
07/01/1988 - "Human serum samples (10 microliters) were incubated in high ionic strength buffer (400 mM KCl) for 16 h at 0 C with [3H]Mibolerone-labeled cytosol (100-200 fmol AR) from Dunning tumors. "
01/01/1985 - "No such tumors were found in 60 vehicle control animals or 55 animals given exaggerated doses of mibolerone. "
01/01/1978 - "These findings on immunocompetence to infectious agents are important because we have previously shown that the administration of mibolerone prevents the development of lymphoid leukosis tumors."
01/01/1985 - "A study to determine the efficacy and safety of mibolerone following prolonged oral administration in the female dog was terminated after 9.6 yr. Histopathologic examination revealed the presence of small dense tumors in the ovaries of 12 of 92 dogs given mibolerone at the approximate efficacious dose. "
08/28/1990 - "They further suggest that high affinity androgens labeled with suitable radionuclides--particularly derivatives of mibolerone (Mib) or methyltrienolone (R1881)--may be effective receptor-based imaging agents for androgen target tissues and tumors, even when patients are already receiving hormonal therapy."
12/01/1993 - "In rat thecal-interstitial cells (TIC), treatment with the synthetic androgen mibolerone has led to the documentation of an autoregulatory process for androgen production. "
12/01/1993 - "Additional studies revealed that the administration of a 1-microM dose of the L-type Ca2+ channel blocker verapamil to TIC cultures was able to partially block the inhibitory effect of mibolerone on androgen synthesis. "
10/01/1985 - "Treatment with 0.01 or 0.1 micrograms of mibolerone caused slight or no bursal atrophy, 1 microgram caused substantial bursal atrophy, and 10 or 100 micrograms caused severe bursal atrophy at the time of hatching and at 6 weeks of age. "
01/01/1985 - "Mibolerone caused bursal atrophy in a dose-dependent manner with severe atrophy at the 10 micrograms dose, substantial atrophy at the 1 microgram dose, and very little or no atrophy at the 0.1 microgram dose. "
04/01/1980 - "Chickens fed a ration containing mibolerone at 1.5 parts per million (ppm) developed bursal atrophy by 4 weeks of age. "
04/01/1977 - "Mibolerone appears to prevent LL development by producing early bursal atrophy of key target cells. "
04/01/1977 - "The bursal lymphocytic follicles atrophied significantly with both the 1- and 4-microng doses; but, on the basis of histologic examination, atrophy was more complete with the 1-microng dose of mibolerone administered during the first 49 days of age. "
|2.||Messenger RNA (mRNA)
|6.||imidazole mustard (BIC)
|10.||Complementary DNA (cDNA)